The Xolair Pregnancy Registry (EXPECT): Perinatal outcomes among pregnant women with asthma treated with omalizumab (Xolair) compared against those of a cohort of pregnant women with moderate-to-severe asthma

Namazy, Jennifer A.; Blais, Lucie; Andrews, Elizabeth; Scheuerle, Angela E.; Cabana, Michael D.; Thorp, John M.; Veith, Joachim; Umetsu, Dale T.; Sun, Diana; Kaufman, Derrick; Covington, Deborah L.; Mukhopadhyay, Santanu; Fogel, Robert; López-Léon, Sandra; Spain, Vic

doi:10.1016/j.jaci.2018.12.312

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the EXPECT study showed no evidence of an increased risk of major congenital anomalies with omalizumab in 250 pregnant women treated with anti-IgE therapy. 96 Ligelizumab, the second generation anti-IgE antibody, which is currently under development, has shown promising results in patients with CSU, but was unable to demonstrate significant improvement in symptoms of asthma versus placebo. 97 This may indicate that ligelizumab has a slightly different mechanism of action or drug distribution than omalizumab.…”

Section: Discussionmentioning

confidence: 99%

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Wollenberg

Thomsen

Lacour

et al. 2021

World Allergy Organization Journal

View full text Add to dashboard Cite

Immunoglobulin E (IgE) plays an essential role in many allergic diseases. This review highlights the role of IgE in atopic dermatitis (AD), a common, chronic, and complex skin inflammation, and the available therapeutic approaches that target IgE in AD. We examine the existing data showing the use of omalizumab, the only biologic anti-IgE therapy available in clinical use, plasma apheresis, and a combination of both therapeutic approaches for the treatment of AD. Existing data on the efficacy of omalizumab in AD are inconclusive. A limited number of randomised controlled studies, few uncontrolled prospective and retrospective reports, as well as multiple case series and case reports observed varying degrees of the efficacy of omalizumab in AD. Omalizumab displays a trend of higher efficacy in AD patients with low IgE levels compared with those with very high-to-extremely high serum IgE concentrations. Plasma apheresis and its combination with omalizumab show good efficacy, even in patients with unusually high serum IgE concentrations. Combining apheresis and anti-IgE treatment may serve as a comprehensive therapeutic approach for patients with elevated levels of IgE. Dedicated clinical studies with robust study designs are needed to establish the therapeutic efficacy of omalizumab in AD.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Wollenberg

Thomsen

Lacour

et al. 2021

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

“…Kondisi asma yang tidak terkontrol dapat menimbulkan masalah pada bayi yaitu peningkatan kematian perinatal, pertumbuhan janin terhambat, lahir prematur, peningkatan operasi caesar, BBLR dan perdarahan pasca partus. 3 Data penelitian kasus kontrol menyatakan serangan asma terjadi dalam 12 bulan sebelumnya merupakan faktor risiko persalinan prematur yang dapat menurunkan reaktivitas dan agregasi platelet melalui peningkatan Siklus Adenosin Monofosfat (SAMP). Risiko preeklampsia juga meningkat pada ibu hamil dengan asma persisten sedang sampai berat dan teofilin dikatakan dapat menurunkan risiko preeklampsia.…”

Section: Pendahuluanunclassified

“…Nitrogliserin telah dilaporkan secara anekdot dapat membalikkan bronkospasme akut, mungkin melalui relaksasi otot polos langsung. 3…”

Section: Anestesi Untuk Seksio Sesarea Pasien Asmaunclassified

Manajemen Anestesi pada Seksio Sesarea dengan Serangan Asma

Supraptomo¹

2022

JAOI

View full text Add to dashboard Cite

Seksio sesarea adalah sebuah prosedur dimana bayi dilahirkan melalui sebuah insisi pada dinding abdomen dan uterus ibu hamil. Selama persiapan dan pelaksanaan seksio sesarea, pada ibu hamil dengan asma, dapat terjadi serangan asma, yaitu hiperresponsif jalan nafas (respon penyempitan dan edema jalan napas yang berlebihan terhadap pemicu, seperti alergen dan olahraga), dengan gejala mengi, dispnea (sesak napas), dan batuk. Serangan asma ini dapat diakibatkan pelepasan epitel, fibrosis subepitel, peningkatan jumlah dan volume sel mukosa di epitel, hiperplasia otot polos jalan napas, dan hipertrofi, serta peningkatan vaskularisasi dinding jalan napas. Manajemen serangan asma pada seksio sesarea dipengaruhi oleh teknik anestesi yang digunakan. Manajemen serangan asma pada seksio sesarea dengan anestesi regional, dapat menggunakan lidokain 1-2 mg/kgBB IV. Serangan asma pada seksio sesarea dengan anestesi umum dapat dicegah dengan kortikosteroid inhalasi seperti beclomethason 400 μg per hari. Perawatan harus diambil untuk mencegah aspirasi selama intubasi. Jika mungkin, pasien harus ditempatkan dengan kepala tempat tidur ditinggikan untuk mencegah pneumonia terkait aspirasi dan eksaserbasi asma

show abstract

European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned

Conti,

Backer,

Fokkens

et al. 2024

Front. Allergy

View full text Add to dashboard Cite

The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized the first European Biologic Training Course (EBTC) in Brussels on 1st March 2024. The aim of this hybrid EBTC including both face-to-face and web-based participation was to address the educational needs of physicians dealing with asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on the clinically relevant aspects of diagnosing and treatment with biologics. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in faculty coming from the paediatric, allergology, pulmonology, and Ear, Nose and Throat (ENT) speciality and from different continents, with more than 250 participants from over 30 countries in the first EBTC. The current report provides a comprehensive overview of key statements made by the faculty of the EBTC 2024, especially focusing on patient selection for a biologic drug, the communication with patients, the onset of biological treatment and the follow-up in routine clinical practice.

show abstract

The Xolair Pregnancy Registry (EXPECT): Perinatal outcomes among pregnant women with asthma treated with omalizumab (Xolair) compared against those of a cohort of pregnant women with moderate-to-severe asthma

Cited by 3 publications

References 0 publications

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Manajemen Anestesi pada Seksio Sesarea dengan Serangan Asma

European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned

Contact Info

Product

Resources

About